Efficacy of praziquantel treatment of schistosomiasis in a non-endemic country: a follow-up of parasitological, clinical and immunological parameters
Jazyk angličtina Země Česko Médium print
Typ dokumentu časopisecké články
PubMed
1300350
Knihovny.cz E-zdroje
- MeSH
- dospělí MeSH
- feces parazitologie MeSH
- kohortové studie MeSH
- kolon patologie MeSH
- lidé MeSH
- nemoci močového měchýře farmakoterapie imunologie patologie MeSH
- praziquantel terapeutické užití MeSH
- protilátky helmintové krev MeSH
- Schistosoma haematobium imunologie MeSH
- Schistosoma mansoni imunologie MeSH
- schistosomiasis haematobia farmakoterapie imunologie patologie MeSH
- schistosomiasis mansoni farmakoterapie imunologie patologie MeSH
- výsledek terapie MeSH
- zvířata MeSH
- Check Tag
- dospělí MeSH
- lidé MeSH
- mužské pohlaví MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
- Názvy látek
- praziquantel MeSH
- protilátky helmintové MeSH
Schistosomiasis patients were immigrants to Czechoslovakia from Angola and Yemen. Most of them had light or moderate infections and felt subjectively healthy. They received treatment with praziquantel (two doses with a total of 40 mg/kg) and were followed up for several years. In nine of 13 patients, Schistosoma haematobium or S. mansoni eggs with undamaged miracidia were detected in biopsies from the bladder or the rectum one year or later after treatment. Granulomatous reactions in the rectum and bladder lesions of stage 1 including thickened bladder walls persisted in most of the patients. Antibody levels against adult S. mansoni worm antigen remained elevated for at least two years after therapy in some patients and declined in others. Among the nine patients, for whom pre- and post-treatment sera were available, the changes in relative levels of antibodies did not strictly correlate with the continued presence of schistosome eggs in, or their absence from, biopsies. We discuss the results obtained with sensitive diagnostic techniques in the absence of subjectively perceived disease.